Success for oral antisense therapy

Drug Discovery Today

Volumn 8, Issue 12, 2003, Pages 516-517

  Sussman, Hillary E ^a  

^a NONE

Author keywords

Antisense; Biochemistry; Drug Discovery; Molecular Medicine; Myasthenia gravis; Oligonucleotides; Oral

Indexed keywords

ACETYLCHOLINE; ANTISENSE OLIGONUCLEOTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EN 101; MESSENGER RNA; PYRIDOSTIGMINE; RIBONUCLEASE;

ABDOMINAL PAIN; AUTOIMMUNE DISEASE; CELL TYPE; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIPLOPIA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STABILITY; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVITY; GENE EXPRESSION; GENE TARGETING; HUMAN; HYDROLYSIS; IMMUNE RESPONSE; LOW DRUG DOSE; MUSCLE CONTRACTION; MUSCLE CRAMP; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; PHARMACOLOGICAL BLOCKING; RECEPTOR DOWN REGULATION; RNA SPLICING; SHORT SURVEY; TREATMENT OUTCOME;

ACETYLCHOLINESTERASE; ADMINISTRATION, ORAL; CLINICAL TRIALS; HUMANS; ISOENZYMES; MYASTHENIA GRAVIS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0038122882     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02744-2     Document Type: Short Survey

References (4)

1. Argov, Z. et al. (2003) EN101: A novel antisense therapeutic strategy for Myasthenia Gravis (MG). American Academy of Neurology, 55th Annual Meeting, 29 March - 5 April 2003, Honolulu, HI, USA (Abstract SLB.002).
2. Opalinska J.B., Gewirtz A.M. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1:2002;503-514.
3. Mershorer E., Soreq M. Pre-mRNA splicing modulations in senescence. Aging Cell. 1:2002;10-16.
4. Soreq H., Seidman Shlomo. Anti-sense approach to anticholinesterase therapeutics. IMAJ. 2:2000;81-85.